Cannabis Use Is Associated With an Increased Risk of Intestinal Obstruction in Patients Hospitalized With Diverticulitis

Daniel Rim ¹, Alexander Kaye ¹, Akash Ranpura ¹, Siddharth Verma ²

¹. Internal Medicine, Rutgers University, Newark, USA ². Gastroenterology and Hepatology, Veterans Affairs Medical Center, East Orange, USA

Corresponding author: Daniel Rim, danielsrim@gmail.com

Abstract

Objectives
Diverticulitis is a common cause of hospitalization. The use of substances such as tobacco and alcohol can predispose patients to diverticulitis, and smoking is also associated with an increased risk of diverticulitis complications. Cannabis availability is growing in the United States, but there is a lack of data on the effects of cannabis use on the outcomes of diverticulitis. Thus, we investigated the effects of cannabis use on diverticulitis outcomes.

Methods
A retrospective analysis was conducted using 2014 data from the National Inpatient Sample. Patient demographics and outcomes of diverticulitis were compared between the groups with and without a history of cannabis use. The outcomes of interest were inpatient mortality, length of stay, total hospital charge, intestinal obstruction, shock/hypotension, colectomy, intestinal abscess, intestinal fistula, and intestinal perforation.

Results
Among 48,214 patients with diverticulitis, 447 patients had a history of cannabis use. Patients with a history of cannabis use were younger, more likely to be male, less likely to be White, had a lower Charlson Comorbidity Index, and had shorter hospital stays. There were no significant differences in inpatient mortality and total hospital charge. After adjusting for age, sex, race, and the Charlson Comorbidity Index, cannabis use was an independent risk factor for intestinal obstruction in patients hospitalized with diverticulitis. There were no statistically significant differences in other outcomes.

Conclusions
This study indicates that patients hospitalized with diverticulitis with a history of cannabis use are more likely to have an intestinal obstruction. Inhibition of gastrointestinal motility by cannabis in the setting of diverticular inflammation may explain this finding.

Categories: Internal Medicine, Gastroenterology
Keywords: diverticulitis, diverticular disease, cannabis, intestinal obstruction, patient outcomes

Introduction
Diverticulitis is a well-known colonic pathology that is caused by the inflammation or infection of the divertica. Diverticular disease is common with a prevalence as high as 65% in patients aged 85 years; about 10-25% of these patients develop the symptomatic disease at some point [1,2]. Several non-modifiable risk factors associated with diverticulitis include older age, male sex, and certain genetic syndromes such as Marfan and Ehlers-Danlos [3].

Notably, the lifestyle of patients plays an important role in the likelihood of developing an episode of diverticulitis. Some modifiable risk factors that may increase the risk of diverticulosis and diverticulitis include red meat consumption, certain medications such as steroids and opiates, and specific comorbidities such as obesity, hypertension, hypothyroidism, and type 2 diabetes [3,4]; Non-medicinal substances can also impact a patient’s likelihood of developing diverticulitis. Smoking is a well-known independent risk factor for the development of diverticulitis [5]. In addition to an increased incidence of diverticulitis, smoking has been associated with an increased rate of complications and longer hospital stays for diverticulitis patients [6]. In the younger adult population, chronic alcohol use can also increase the likelihood of an episode of diverticulitis, and alcohol use, in general, is associated with an increased rate of diverticulitis recurrence [3,7,8]. Despite the popularity of cannabis, there is currently little data exploring the connection between the
use of this substance and how it impacts the risk of developing or the severity of diverticulitis.

Cannabis has recently become more readily available to the general population. As of May 2021, 36 states have approved the use of cannabis for specific medical indications, and 17 states and Washington D.C. have legalized the use of recreational marijuana as well [9]. Cannabis can impact gastric emptying and colonic motility due to the cannabinoid receptors found along the gastrointestinal tract [10]. More specifically, activation of the cannabinoid receptors is known to cause inhibition of peristalsis, gastric acid secretion, and decreased colonic motility [11]. Furthermore, cannabis can cause gastrointestinal dysmotility [10].

Given that cannabis is growing in availability and its known impact on gastrointestinal tract motility, it is important to understand better how this substance may impact diverticulitis. Therefore, this study further explores the outcomes of patients with diverticulitis who have a history of cannabis use at a national level.

This article was previously presented as a poster at the Annual Department of Medicine Research Day on May 27, 2021.

**Materials And Methods**

This is a retrospective cohort study using data from the National Inpatient Sample (NIS), 2014, Healthcare Cost and Utilization Project (HCUP), and Agency for Healthcare Research and Quality, which is known as the largest all-payer inpatient database in the United States [12]. Adult patients aged 18 years and above hospitalized with diverticulitis were included in the study. The International Classification of Diseases-Ninth Edition Revision, Clinical Modification (ICD-9 CM) codes were used to identify diagnoses in this database. Patients were then divided into two groups: those with and without a history of cannabis use. Patient demographics and characteristics including age, sex, race, and the Charlson Comorbidity Index were compared between the groups. The Charlson Comorbidity Index is a tool frequently used for comorbidity adjustment for confounding [13,14]. The clinical outcomes of diverticulitis including inpatient mortality, length of stay, total hospital charge, hypotension/shock, intestinal abscess, intestinal obstruction, intestinal fistula, intestinal perforation, and colectomy were compared.

SPSS version 26.0 (Armonk, NY: IBM Corp) was used for statistical analyses. Chi-squared tests and independent t-tests were used to compare proportions and means, respectively. Statistical analyses performed in this study were two-tailed, and a p-value less than 0.05 was considered statistically significant. Multivariate logistic regression analysis was performed to determine if cannabis use is an independent predictor for the clinical outcomes, adjusting for age, sex, race, and the Charlson Comorbidity Index.

**Results**

Among 48,214 patients with diverticulitis identified in the study, 447 patients had a history of cannabis use. Patient demographics, characteristics, length of stay, inpatient mortality, and total hospital charge are demonstrated in Table 1. Among patients hospitalized with diverticulitis, those with cannabis use were younger (45.8 vs 60.6, p < 0.05), more likely to be male (74.5% vs. 41.5%, p < 0.05), less likely to be White (60.1% vs. 77.3%, p < 0.05), had lower Charlson Comorbidity Index (1.1 vs. 2.5, p < 0.05), and had shorter length of stay (4.3 days vs. 4.7 days, p < 0.05). There were no statistically significant differences in inpatient mortality (0% vs. 0.4%, p = 0.20) and total hospital charge ($36,573 vs. $38,568, p = 0.45).
TABLE 1: Demographics, characteristics, length of stay, total hospital charge, and inpatient mortality among diverticulitis patients with and without a history of cannabis use

*Exact numbers are not included in the table due to small sample sizes.

Table 2 compares clinical outcomes of diverticulitis in groups with and without a history of cannabis use. Patients with a history of cannabis use had a higher prevalence of intestinal abscess (19.5% vs. 15.2%, p < 0.05). There were no statistically significant differences in the prevalence of shock/hypotension, colectomy, intestinal obstruction, intestinal fistula, or intestinal perforation. Due to small sample sizes of shock/hypotension, intestinal fistula, and intestinal perforation, further analysis of these outcomes was not performed.

Table 3 shows odds ratios of clinical outcomes after adjusting for age, sex, race, and the Charlson Comorbidity Index.

2021 Rim et al. Cureus 13(7): e16768. DOI 10.7759/cureus.16768
Comorbidity Index. Cannabis use was an independent risk factor for intestinal obstruction (adjusted odds ratio (aOR) 1.69, 95% confidence interval (CI): 1.05-2.73, p < 0.05). However, adjusted odds ratios of colectomy (aOR 0.83, 95% CI: 0.61-1.13, p = 0.23) and intestinal abscess (aOR 1.20, 95% CI: 0.95-1.53, p = 0.13) were not statistically significant.

| Outcomes           | Adjusted odds ratio* (95% CI) | p-Value |
|--------------------|-------------------------------|---------|
| Colectomy          | 0.83 (0.61-1.13)              | 0.23    |
| Intestinal abscess | 1.20 (0.95-1.53)              | 0.13    |
| Intestinal obstruction | 1.69 (1.05-2.73)          | <0.05   |

**TABLE 3: Multivariate logistic regression analysis of clinical outcomes**

*Adjusted for age, sex, race, and the Charlson Comorbidity Index.

**Discussion**

Prior to this study, it was established that cannabis could cause gastric dysmotility through its activation of cannabinoid receptors found along the gastrointestinal tract. Despite cannabis’ known impact on gastric emptying and motility, it was unclear how cannabis affects the disease course of diverticulitis. This study showed how cannabis use can affect the outcomes of diverticulitis. As shown above, these data demonstrate that patients hospitalized with diverticulitis with a history of cannabis use have an increased rate of intestinal obstruction. This is an important finding as intestinal obstruction carries with it an elevated mortality risk [15]. While increased mortality was not appreciated in this study, given that marijuana use is becoming increasingly more widespread and popular, this is a consideration that primary care providers should counsel their patients on. In addition, at the population level, anticipating an increased frequency of intestinal obstruction cases secondary to cannabis use, there will be an increased economic burden on the healthcare system. The increased number of visits to primary care physicians and gastroenterologists for evaluation of symptoms caused by an intestinal obstruction in cannabis users is also anticipated.

Despite the increased risk of intestinal obstruction, the use of cannabis in diverticulitis patients did not affect rates of other outcomes. These findings can be explained by the role of cannabinoid receptors located in the colon. Through activation of the cannabinoid receptors, colonic motility is decreased, which may be the primary instigator of the intestinal obstruction [11,16]. While colonic motility is decreased, some data indicate a potential protective effect that cannabinoids may provide. There is evidence in animal models supporting a protective role of cannabinoids in the setting of inflammatory bowel disease by decreasing inflammatory damage and diarrhea [11,17]. As diverticulitis is also a state of intestinal inflammation, it is possible to extrapolate that cannabis use should not worsen the outcomes related to inflammation, such as colectomy and intestinal abscess.

This study has several limitations. Regarding the diagnosis of cannabis use, ICD-9 coding only allows for the indication of whether the patient is using a cannabis product without a quantitative measurement. Without the ability to quantify how much cannabis a patient with diverticulitis may be using, it is difficult to assess if the risk of intestinal obstruction is dose-dependent or if the risk of intestinal obstruction is the same regardless of the amount of cannabis used.

This analysis is also limited by the functionality of performing research with the NIS database. NIS relies on accurate billing code inputs by healthcare providers. Inaccurate billing can result in the frequency of diverticulitis, cannabis use, and the risk for complications being over or underrepresented. The illegality of cannabis use in many states in the United States in previous years may have contributed to underreporting of its use. An additional limitation of NIS is that it only represents patients that have been hospitalized. Under 20% of patients who present for evaluation of diverticular disease require hospitalization, indicating that the results of this study may not represent those who are not hospitalized [18]. Despite these limitations, one of the greatest strengths of this study is the large sample size, which allows the estimation of patient characteristics and outcomes at a national level. In addition, this study was bolstered by the multivariate logistic regression analysis that adjusted for potential confounding factors.

**Conclusions**

In summary, patients with a history of cannabis use who develop diverticulitis are at increased risk for intestinal obstruction, while its use does not seem to play a significant role in altering other outcomes or the prognosis of patients suffering from diverticulitis. This study will become more relevant as more and more states legalize recreational cannabis, thus increasing the access and its use and provides data to better counsel patients about cannabis use. Additional research into the therapeutic aspects as well as adverse
events from the use of cannabis is necessary to meet the increased use of this substance among the adult patient population.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Weizman AV, Nguyen GC: Diverticular disease: epidemiology and management. Can J Gastroenterol. 2011, 25:385-9. 10.1155/2011/795241
2. Matrana MR, Margolin DA: Epidemiology and pathophysiology of diverticular disease. Clin Colon Rectal Surg. 2009, 22:141-6. 10.1055/s-0029-1256157
3. Böhm SK: Risk factors for diverticulosis, diverticulitis, diverticular perforation, and bleeding: a plea for more subtle history taking. Vizualmedizin. 2015, 31:84-94. 10.1159/0003581867
4. Violi A, Cambiè G, Miraglia C, et al.: Epidemiology and risk factors for diverticular disease. Acta Biomed. 2018, 89:107-12. 10.23750/abm.v89i9-S.7924
5. Liu PH, Cao Y, Keeley BR, et al.: Adherence to a healthy lifestyle is associated with a lower risk of diverticulitis among men. Am J Gastroenterol. 2017, 112:1868-76. 10.1038/ajg.2017.398
6. Gayam V, Koirala S, Garlapati PR, Mandal AK: Outcomes of diverticulitis in patients with tobacco smoking: a propensity-matched analysis of nationwide inpatient sample. Int J Colorectal Dis. 2021, 36:1033-42. 10.1007/s00384-020-05805-6
7. Pinana A, Vacca V, Reccia I, Poddà M, Uccheddu A: Acute diverticulitis in the young: the same disease in a different patient. Gastroenterol Res Pract. 2015, 2015:867961. 10.1155/2015/867961
8. Kim YC, Chung JW, Baek JH, et al.: Risk factors for recurrence of right colonic diverticulitis. Dig Surg. 2019, 36:509-13. 10.1159/000494297
9. National conference of state legislatures. State medical marijuana laws. (2021). Accessed: June 7, 2021: https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx
10. Camilleri M: Cannabinoids and gastrointestinal motility: pharmacology, clinical effects, and potential therapeutics in humans. Neurogastroenterol Motil. 2018, 30:13370. 10.1111/nmo.13370
11. DiPatrizio NV: Endocannabinoids in the gut. Cannabis Cannabinoid Res. 2016, 1:67-77. 10.1089/can.2016.0001
12. HCUP national inpatient sample (NIS). Healthcare cost and utilization project (HCUP). (2014). Accessed: June 7, 2021: http://www.hcup-us.ahrq.gov/nisoverview.jsp
13. Austin SR, Wong YN, Uzzo RG, Beck JR, Egleston BL: Why summary comorbidity measures such as the Charlson comorbidity index and Elixhauser score work. Med Care. 2015, 53:65-72. 10.1097/MLR.0b013e3182927972
14. Charlson ME, Pompei P, Alex KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987, 40:373-83. 10.1016/0021-9681(87)90171-8
15. Chen ZX, Wei T, Jiang K, et al.: Etiological factors and mortality of acute intestinal obstruction: a review of 705 cases. Zhong Xi Yi Jie He Xue Bao. 2008, 6:1010-6.
16. Wong BS, Camilleri M, Buciglio J, Carlson P, Szarka LA, Burton D, Zinsmeister AR: Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology. 2011, 141:1638-47. 10.1053/j.gastro.2011.07.036
17. Pesce M, Esposito G, Sarnelli G: Endocannabinoids in the treatment of gastrointestinal inflammation and symptoms. Curr Opin Pharmacol. 2018, 45:81-6. 10.1016/j.coph.2018.08.009
18. Reddy VB, Longo WE: The burden of diverticular disease on patients and healthcare systems. Gastroenterol Hepatol (N Y). 2013, 9:21-7.